Ledraxen

Enoxaparin sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous or haemodialysis use. It is employed to prevent and treat deep vein thrombosis, pulmonary embolism, and to provide anticoagulation during haemodialysis procedures.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and transplant centres worldwide, ensuring quality and regulatory compliance. Our distribution network spans Europe, Asia and the Americas, providing reliable access to essential anticoagulant therapy.

Ledraxen, a low molecular weight heparin, is indicated for several thromboembolic conditions.

- Deep vein thrombosis: prevents clot formation and treats existing DVT in at‑risk patients, reducing the chance of vein obstruction and post‑thrombotic syndrome. - Pulmonary embolism: reduces risk of embolic events and treats confirmed PE, helping to restore pulmonary circulation and improve oxygenation. - Hemodialysis anticoagulation: maintains circuit patency by preventing clotting during dialysis sessions, allowing effective blood purification without interruption.

Enoxaparin sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain or erythema - Minor bruising or hematoma at injection site - Nausea or mild gastrointestinal upset - Headache - Elevated liver enzymes

Serious or Rare Side Effects: - Major bleeding, including intracranial or gastrointestinal hemorrhage - Heparin‑induced thrombocytopenia (HIT) - Spinal or epidural hematoma, especially after neuraxial procedures - Severe allergic reactions such as anaphylaxis

When using Ledraxen, clinicians should observe specific precautions to minimize risk and ensure efficacy. - Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function. - Concomitant anticoagulants: avoid or closely monitor use with warfarin, direct thrombin inhibitors, or antiplatelet agents. - Surgery or invasive procedures: discontinue before major surgery to reduce bleeding risk. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Platelet monitoring: check platelet counts regularly to detect heparin‑induced thrombocytopenia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin sodium can interact with other medicines, affecting anticoagulant activity or bleeding risk.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, dabigatran, rivaroxaban) may cause uncontrolled bleeding. - Antiplatelet drugs (aspirin, clopidogrel, ticagrelor) increase hemorrhagic risk. - Fibrinolytic agents (alteplase, streptokinase) potentiate anticoagulation. - Neuraxial anesthesia or spinal puncture: heightened risk of spinal hematoma.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) can augment bleeding tendency. - Selective serotonin reuptake inhibitors (SSRIs) may increase risk of gastrointestinal bleeding. - Heparin products: combined use may trigger thrombocytopenia; monitor platelet counts.